NASDAQ:SYBX

Synlogic Stock Forecast, Price & News

$3.11
-0.38 (-10.89 %)
(As of 09/23/2021 10:32 AM ET)
Add
Compare
Today's Range
$3.10
$3.28
50-Day Range
$2.45
$3.71
52-Week Range
$1.78
$5.11
Volume53,158 shs
Average Volume658,109 shs
Market Capitalization$162.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
30 days | 90 days | 365 days | Advanced Chart
Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.


Synlogic logo

About Synlogic

Synlogic, Inc. engages in the discovery and development of Synthetic Biotic medicines. It focuses in Phenylketonuria, Enteric Hyperoxaluria, Immuno Oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

484th out of 1,352 stocks

Pharmaceutical Preparations Industry

234th out of 665 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Synlogic (NASDAQ:SYBX) Frequently Asked Questions

Is Synlogic a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic
or view top-rated stocks.

What stocks does MarketBeat like better than Synlogic?

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synlogic wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Synlogic
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) issued its quarterly earnings data on Thursday, August, 12th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.01. The biotechnology company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.20 million.
View Synlogic's earnings history
.

How has Synlogic's stock been impacted by COVID-19 (Coronavirus)?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYBX stock has increased by 107.8% and is now trading at $3.20.
View which stocks have been most impacted by COVID-19
.

When did Synlogic's stock split? How did Synlogic's stock split work?

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

6 equities research analysts have issued 1-year price objectives for Synlogic's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Synlogic's stock price to reach $11.60 in the next year. This suggests a possible upside of 262.5% from the stock's current price.
View analysts' price targets for Synlogic
or view top-rated stocks among Wall Street analysts.

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Aoife M. Brennan, President, Chief Executive Officer & Director
  • Antoine Awad, Chief Operating Officer
  • Gregg D. Beloff, Chief Financial Officer
  • David L. Hava, Chief Scientific Officer
  • Amanda Kay, Senior VP, Head-Business Development & Strategy

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (3.30%), Dimensional Fund Advisors LP (1.82%), Ikarian Capital LLC (1.62%), Alyeska Investment Group L.P. (1.53%) and LMR Partners LLP (0.57%).
View institutional ownership trends for Synlogic
.

Which major investors are selling Synlogic stock?

SYBX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Squarepoint Ops LLC, Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, and Susquehanna International Group LLP.
View insider buying and selling activity for Synlogic
or view top insider-selling stocks.

Which major investors are buying Synlogic stock?

SYBX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Alyeska Investment Group L.P., LMR Partners LLP, Maven Securities LTD, Geode Capital Management LLC, Millennium Management LLC, and State Street Corp.
View insider buying and selling activity for Synlogic
or or view top insider-buying stocks.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $3.20.

How much money does Synlogic make?

Synlogic has a market capitalization of $167.59 million and generates $550,000.00 in revenue each year. The biotechnology company earns $-59,170,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 72 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

Where are Synlogic's headquarters?

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at (617) 401-9975 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.